Abstract
Pyridox(am)ine 5′-phosphate oxidase deficiency results in an early-onset neonatal encephalopathy that can be fatal if not detected and treated early. The condition is rare, can result in preterm delivery, and can mimic hypoxic ischemic encephalopathy. Thus, suspicion of the diagnosis, appropriate investigations, and therapeutic trials with pyridoxal-5′-phosphate are often delayed. In this paper we report four cases of pyridox(am)ine 5′-phosphate oxidase deficiency, two of whom are siblings. Three were treated with pyridoxal-5′-phosphate in the first few days of life and the fourth within the first month. One of the siblings was electively treated from birth until a diagnosis was secured. Our cases demonstrate that early diagnosis and treatment can be associated with normal neurodevelopment in childhood. We suggest that a low threshold for investigating for pyridox(am)ine 5′-phosphate oxidase deficiency and electively treating with pyridoxal-5′-phosphate is considered in any neonate with encephalopathy, including those with presumed hypoxic ischemic encephalopathy in whom the degree of encephalopathy is not expected from perinatal history, cord gases and/or neuroimaging.
Competing interests: None declared
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albersen M, Groenendaal F, van der Ham M, de Koning TJ et al (2012) Vitamin B6 vitamer concentrations in cerebrospinal fluid differ between preterm and term newborn infants. Pediatrics 130(1):e191–e198
Bagci S, Zschocke J, Hoffmann GF et al (2008) Pyridoxal phosphate-dependent neonatal epileptic encephalopathy. Arch Dis Child Fetal Neonatal Ed 93(2):F151–F152
Clayton PT (2006) B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis 29(2–3):317–326
Footitt EJ, Heales SJ, Mills PB, Allen GF, Oppenheim M, Clayton PT (2011) Pyridoxal 5′-phosphate in cerebrospinal fluid; factors affecting concentration. J Inherit Metab Dis 34(2):529–538
Goyal M, Fequiere PR, McGrath TM, Hyland K (2013) Seizures with decreased levels of pyridoxal phosphate in cerebrospinal fluid. Pediatr Neurol 48(3):227–231
Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE (2008) A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 199(6):587–595
Hoffmann GF, Schmitt B, Windfuhr M et al (2007) Pyridoxal 5′-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 30(1):96–99
Khayat M, Korman SH, Frankel P et al (2008) PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism. Mol Genet Metab 94(4):431–434
Mills PB, Surtees RA, Champion MP et al (2005) Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet 14(8):1077–1086
Mills PB, Camuzeaux SS, Footitt EJ et al (2014) Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 137:1350–1360
Ormazabal A, Oppenheim M, Serrano M et al (2008) Pyridoxal 5′-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab 94(2):173–177
Pearl PL, Hyland K, Chiles J, McGavin CL, Yu Y, Taylor D (2013) Partial pyridoxine responsiveness in PNPO deficiency. JIMD Rep 9:139–142
Plecko B, Paul K, Mills P et al (2014) Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology 82(16):1425–1433
Porri S, Fluss J, Plecko B, Paschke E, Korff CM, Kern I (2014) Positive outcome following early diagnosis and treatment of pyridoxal-5′-phosphate oxidase deficiency: a case report. Neuropediatrics 45(1):64–68
Ruiz A, García-Villoria J, Ormazabal A et al (2008) A new fatal case of pyridox(am)ine 5′-phosphate oxidase (PNPO) deficiency. Mol Genet Metab 93(2):216–218
Schmitt B, Baumgartner M, Mills PB, Clayton PT, Jakobs C, Keller E, Wohlrab G (2010) Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol 52(7):e133–e142
Stockler S, Plecko B, Gospe SM Jr et al (2011) Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 104(1–2):48–60
Sudarsanam A, Singh H, Wilcken B et al (2014) Cirrhosis associated with pyridoxal 5′-phosphate treatment of pyridoxamine 5′-phosphate oxidase deficiency. JIMD Rep 17:67–70
Van Hove J, Lohr N (2011) Metabolic and monogenic causes of seizures in neonates and young infants. Mol Genet Metab 104:214–230
Veerapandiyan A, Winchester SA, Gallentine WB, Smith EC, Kansagra S, Hyland K, Mikati MA (2011) Electroencephalographic and seizure manifestations of pyridoxal 5′-phosphate-dependent epilepsy. Epilepsy Behav 20(3):494–501
Ware TL, Earl J, Salomons GS, Struys EA, Peters HL, Howell KB, Pitt JJ, Freeman JL (2014) Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment. Dev Med Child Neurol 56(5):498–502
Acknowledgements
The authors thank Medical Neurogenetics, Atlanta, for sequencing the PNPO gene in cases 1 and 2. The authors sincerely thank the families of the cases discussed in this paper.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: John Christodoulou, MBBS, PhD, FRACP, FRCPA
Appendices
Compliance with Ethics Guidelines
Conflict of Interest
Joshua Hatch, David Coman, Peter Clayton, Philippa Mills, Sophie Calvert, Richard Webster and Kate Riney declare that they have no conflicts of interest.
Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
Author Contributions
Dr Joshua Hatch has driven the manuscript development.
Professor David Coman is a metabolic physician involved in the care of patients 1–3 and has coordinated the manuscript development and design.
Professor Peter Clayton is a metabolic physician who has provided invaluable clinical advice on all four patients and has been involved in the manuscript development.
Dr Philippa Mills has provided valuable advice regarding the molecular pathogenicity of the mutations identified and has been involved in the manuscript development.
Dr Sophie Calvert is a paediatric neurologist, providing neurology care for case 3, and has been involved in the manuscript development.
Dr Richard Webster is a paediatric neurologist, providing neurology care for case 4, and has been involved in the manuscript development.
Dr Kate Riney is a paediatric neurologist, providing neurology care for cases 1 and 2, and has been involved in the manuscript development.
Rights and permissions
Copyright information
© 2015 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hatch, J. et al. (2015). Normal Neurodevelopmental Outcomes in PNPO Deficiency: A Case Series and Literature Review. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 26. JIMD Reports, vol 26. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2015_482
Download citation
DOI: https://doi.org/10.1007/8904_2015_482
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49832-3
Online ISBN: 978-3-662-49833-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)